Skinfluenced - The Skin Podcast – Details, episodes & analysis

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s recent approval of Libtayo® (Cemiplimab-rwlc) as the first and only adjuvant immunotherapy for patients with high-risk cutaneous squamous cell carcinoma (cSCC) following surgery and radiation.

Join us as we discuss:🧬 The pivotal trial showing improved disease-free survival in high-risk cSCC💉 The evolving role of PD-1 blockade in post-surgical skin cancer management🧠 How this approval changes the treatment landscape for patients at risk of recurrence

This landmark decision represents a major step forward in skin cancer care—bringing immunotherapy into the adjuvant setting and offering new hope for patients facing aggressive or recurrent cSCC.

Link to Source(s):

American Association for Cancer Research. Immunotherapy Approved for Preventing Recurrence of Certain Skin Cancers. Accessed October 22, 2025. https://tinyurl.com/ywpynwfn

American Journal of Managed Care. FDA Approves Cemiplimab as First & Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/5b4s6jb7

Dermatology Advisor. FDA Approves Libtayo for Adjuvant Treatment of High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/58h5cckn

Derm Digest. FDA Approves Cemiplimab to Treat cSCC With High Risk of Recurrence After Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/2s9jjc53

Journal of Clinical Oncology. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Patients With High-Risk Cutaneous Squamous Cell Carcinoma. Published 2025; 43(16_suppl):6000. Accessed October 22, 2025. https://tinyurl.com/27ekuzch

New England Journal of Medicine. Adjuvant Cemiplimab for Cutaneous Squamous-Cell Carcinoma. Published 2025. Accessed October 22, 2025. https://tinyurl.com/4rynuvky

OncLive. Dr. Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma. Accessed October 22, 2025. https://tinyurl.com/4kvzbv8z

Oncology Nursing Society. FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma. Published October 2025. Accessed October 22, 2025. https://tinyurl.com/4ne9rsv3

Regeneron Pharmaceuticals. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Phase 3 Trial. Accessed October 22, 2025. https://tinyurl.com/3a9m5u6c

Regeneron Pharmaceuticals. FDA Approves Libtayo (cemiplimab-rwlc) in the U.S. as the First and Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/2hfs59k2

Regeneron Pharmaceuticals. Libtayo (cemiplimab) Phase 3 Data: Adjuvant Treatment Post-Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/yx5xkzcr

Regeneron Pharmaceuticals. Libtayo Full Prescribing Information. Accessed October 22, 2025. https://tinyurl.com/86w7ydjn

Regeneron Pharmaceuticals. Libtayo Medication Guide. Accessed October 22, 2025. https://tinyurl.com/432jx77u

ScienceDirect. Induction of Natural Cytotoxicity by Interferon: Studies on the Mechanism of Action. Trends in Biochemical Sciences. Published 1985. Accessed October 22, 2025. https://tinyurl.com/589swev2

#SCC #skincancer #skincancertreatment #Dermatology #SkinHealth #NewTreatments #FDAApproved #Therapies #ClinicalGuidelines #FDAApproval #SkinScience #EvidenceBasedMedicine #SCCManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s latest approval of ZORYVE® (roflumilast) Cream 0.05%, marking a new topical treatment option for young children living with atopic dermatitis.

Join us as we discuss:
🌿 Clinical trial data showing safety and efficacy in patients aged 2–5 years
💊 How PDE-4 inhibition with roflumilast differs from current treatment options
🧴 What this means for real-world management of pediatric eczema

This exciting update highlights continued innovation in pediatric dermatology and expands therapeutic options for our youngest patients.

Link to Source(s):

Arcutis. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 for the Treatment of Atopic Dermatitis in Children Ages 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/

Arcutis Biotherapeutics. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 Treatment. Published October 6, 2025. Accessed October 8, 2025. https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment

HCPLive. FDA Approves Roflumilast (Zoryve) Cream 0.05 for Atopic Dermatitis in Children Aged 2-5 Years. Published October 6, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years

HCPLive. Roflumilast Cream 0.05% Effective for Atopic Dermatitis in Patients Aged 2-5 Years. Published February 22, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/roflumilast-cream-0-05-effective-atopic-dermatitis-patients-aged-2-5-years

HCPLive. Significance of Roflumilast Approval in Atopic Dermatitis Children — Lawrence Eichenfield, MD. Published October 8, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/significance-roflumilast-approval-atopic-dermatitis-children-lawrence-eichenfield-md

HMP Global Learning Network / The Derm. FDA Alerts: FDA Approves Roflumilast Cream 0.05 Treatment for Atopic Dermatitis in Children. Published October 6, 2025. Accessed October 8, 2025. https://www.hmpgloballearningnetwork.com/site/thederm/fda-alerts/fda-approves-roflumilast-cream-005-treatment-atopic-dermatitis-children

The Derm Digest. U.S. FDA Approves Roflumilast Cream 0.05 for AD in Kids Aged 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://thedermdigest.com/u-s-fda-approves-roflumilast-cream-0-05-for-ad-in-kids-aged-2-to-5

Zoryve HCP. [Homepage]. Accessed October 8, 2025. https://www.zoryvehcp.com/

#AD #atopicdermatitis #Dermatology #SkinHealth #NewTreatments #FDAApproved #topicalTherapies #ClinicalGuidelines #FDAApproval #UTDDermatology #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we take a closer look at brand new statements released from the FDA discussing hormone replacement therapy (HRT) and how WRONG the FDA and all of medicine was for over 20 years! Our hormones affect aging and our skin in so many ways, these new changes will be revolutionary for the field of medicine and health!

Link to Source(s):

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we’re shining a spotlight on Chronic Hand Eczema (CHE). With the recent approval the first topical treatment for moderate to severe chronic hand eczema, we want to brush everyone up on CHE.

Tune in to discover how this new medication, a topical Janus kinase (JAK) inhibitor, performs against placebo in improving chronic hand eczema. We discuss the clinical benefits, safety profile, and what this means for patients struggling with persistent hand eczema despite conventional therapies.

Link to Source(s):

Mense SA, Maher S, & Chovatiya RA. A Practical Approach to Chronic Hand Eczema: https://rdcu.be/ey3d5

#ChronicHandEczema #CHE #Delgocitinib #JAKInhibitor #HandDermatitis #FDAApproval #InflammatorySkinDisease #TopicalJAKInhibitor #OccupationalEczema #SkinBarrierRepair #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we review Johnson & Johnson’s recent announcement seeking FDA approval for Icotrokinra — a promising new oral medication designed to revolutionize treatment for adults and adolescents with active, moderate-to-severe Plaque Psoriasis.

Tune in to learn how this novel oral IL-23 medication works, its potential to offer a novel approach in managing inflammation and safety data, and what this could mean for patients struggling with moderate-to-severe plaque psoriasis who need new treatment options beyond current therapies.

We’ll break down the drug’s mechanism, the clinical data that supports its use, and how it fits into the evolving landscape of dermatologic care.

Link to Source(s):

Johnson & Johnson Seeks First icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigmfor Adults and Adolescents With Plaque Psoriasis: https://s203.q4cdn.com/636242992/files/doc_news/Johnson--Johnson-seeks-first-icotrokinra-U-S--FDA-approval-aiming-to-revolutionize-treatment-paradigm-for-adults-and-adolescents-with-ABQBI.pdf

#PlaquePsoriasis #Psoriasis #Icotrokinra #IL23Inhibitor #IL23 #NPF #JohnsonAndJohnson #InflammatorySkinDisease #OralTherapiesForPsO #ChronicSkinDisease #BiologicAlternatives #NewFDADrugApproval #SkinBarrierRepair #SkinScience #Dermatology #DermatologyProvider #CosmeticDermatology #Aesthetics #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we take a closer look at a newly published pilot study from the Journal of Cosmetic Dermatology (Feb 2025) that explores whether Tetramethylhexadecenyl Succinoyl Cysteine (TSC) — the active ingredient in Epicutis’ Lipid Serum — can help reduce the irritation commonly associated with tretinoin use.

Tune in to find out what happens when TSC is used in conjunction with tretinoin, and result are seen within just five days! The findings raise interesting questions about the future of barrier-supportive actives in dermatologic therapy.

Link to Source(s):

Pilot Study Demonstrates Tetramethylhexadecenyl Succinoyl Cysteine (TSC) Reduces Tretinoin‑Induced Erythema and Dryness in Human Subjects: https://www.researchgate.net/publication/388790490_Pilot_Study_Demonstrates_Tetramethylhexadecenyl_Succinoyl_Cysteine_TSC_Reduces_Tretinoin-Induced_Erythema_and_Dryness_in_Human_Subjects

Link to Products Discussed in Episode:

https://epicutis.com/products/lipid-serum

#RetinoidIrritation #TretinoinTips #Epicutis #LipidSerum #TSCskincare #BarrierRepair #MedicalGradeSkincare #SensitiveSkinSolutions #AcneCare #AntiAgingSkincare #TSC #SkinScience #Dermatology #DermatologyProvider #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #DermatologyPodcast #SkinfluencedPodcast

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today’s episode.

In this episode of Skinfluenced: The Skin Podcast, we review the FDA’s September 30, 2025 approval of remibrutinib (Rhapsido, Novartis), the first oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). We’ll walk through the press releases, clinical trial data, and recent publications highlighting its efficacy, safety, and potential impact on treatment pathways for CSU.

Link to Source(s):

The American Journal of Managed Care (AJMC). FDA Approves Remibrutinib for Chronic Spontaneous Urticaria. Published September 30, 2025. Accessed October 1, 2025. https://www.ajmc.com/view/fda-approves-remibrutinib-for-chronic-spontaneous-urticaria

BioSpace. Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives. Published September 30, 2025. Accessed October 1, 2025. https://www.biospace.com/fda/novartis-secures-first-fda-approval-of-oral-btk-inhibitor-for-chronic-hives

ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of Remibrutinib in Participants With Chronic Spontaneous Urticaria (NCT05030311). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05030311

ClinicalTrials.gov. A Study of Remibrutinib in Chronic Spontaneous Urticaria (NCT05032157). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05032157

Novartis. Novartis Receives FDA Approval for Rhapsido (Remibrutinib), the Only Oral Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU). Published September 30, 2025. Accessed October 1, 2025. https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu

Practical Dermatology. FDA Approves Remibrutinib for Adults With CSU. Published September 30, 2025. Accessed October 1, 2025. https://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/

Reuters. US FDA Approves Novartis Drug for Skin Disease. Published September 30, 2025. Accessed October 1, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-novartis-drug-skin-disease-2025-09-30/

ScienceDirect. Remibrutinib in Chronic Spontaneous Urticaria: Results From Clinical Trials. Published 2022. Accessed October 1, 2025. https://www.sciencedirect.com/science/article/pii/S0091674922011812

The Derm Digest. Breaking News: The U.S. FDA Approves Remibrutinib (Rhapsido, Novartis) for CSU. Published September 30, 2025. Accessed October 1, 2025. https://thedermdigest.com/breaking-news-the-u-s-fda-approves-remibrutinib-rhapsido-novartis-for-csu/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR

Taylor & Francis Online. Remibrutinib for Chronic Spontaneous Urticaria: Clinical Impact and Future Directions. Published 2025. Accessed October 1, 2025. https://www.tandfonline.com/doi/abs/10.1080/1750743X.2025.2510892

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we review the brand new FDA approval of Opzelura® (ruxolitinib) cream 1.5% for children ages 2 and up with atopic dermatitis. This marks a major step forward in pediatric dermatology, offering the first topical JAK inhibitor option for younger patients with mild-to-moderate AD who need more than topical steroids or topical calcineurin inhibitors.

We’ll discuss the clinical trial data from the TRuE-AD program, safety considerations, and where ruxolitinib cream may fit into the evolving treatment landscape for pediatric eczema. Tune in to learn what this means for providers, patients, and families navigating chronic AD care.

#AtopicDermatitis #Eczema  #PediatricDermatology #Opzelura #Ruxolitinib #JAKInhibitor #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #ClinicalGuidelines #FDAApproval #EczemaTreatment #ADUpdate #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Business Wire. Incyte Announces U.S. FDA Approval of Opzelura (Ruxolitinib) Cream, a Topical JAK Inhibitor, for Treatment of Atopic Dermatitis (AD). Published September 21, 2021. Accessed September 20, 2025. ⁠https://www.businesswire.com/news/home/20210921006072/en/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD⁠

Contemporary Pediatrics. FDA Approves Ruxolitinib for Pediatric Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.contemporarypediatrics.com/view/fda-approves-ruxolitinib-for-pediatric-atopic-dermatitis⁠

Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Vitiligo in Nonsegmental Patients 12 Years and Older. Published July 18, 2022. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/23156/pdf⁠

Incyte. Incyte Announces Positive Topline Results From Pivotal Phase 3 TRuE-AD Clinical Trial Program Evaluating Ruxolitinib Cream for Atopic Dermatitis. Published December 15, 2019. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/23376/pdf⁠

Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Atopic Dermatitis in Pediatric Patients Ages ≥2 Years. Published July 29, 2025. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/25636/pdf⁠

Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Nonsegmental Vitiligo in Patients 12 Years and Older. Published July 18, 2022. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/25226/pdf⁠

Pharmacy Times. FDA Approves 1.5% Ruxolitinib Cream for Pediatric Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.pharmacytimes.com/view/fda-approves-1-5-ruxolitinib-cream-for-pediatric-atopic-dermatitis⁠

The American Journal of Managed Care (AJMC). FDA Approves Ruxolitinib Cream for Patients as Young as 2 Years With Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.ajmc.com/view/fda-approves-ruxolitinib-cream-for-patients-as-young-as-2-years-with-atopic-dermatitis⁠

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we’re breaking down the American Academy of Dermatology’s June 2025 focused update on the management of Atopic Dermatitis (AD) in adults.

We’ll highlight how to integrate the latest high-quality evidence into practice, including new FDA-approved therapies that are reshaping the treatment landscape. From tapinarof and roflumilast creams, to biologics like lebrikizumab and nemolizumab, we review the data behind their efficacy and safety, drawn from multiple randomized controlled trials.

You’ll also learn how these treatments fit within current regimens—whether used alone or in combination—so you can deliver the most accurate, evidence-based care for your AD patients.
#AtopicDermatitis #Eczema #ADGuidelines #AADGuidelines #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #SystemicTherapies #Lebrikizumab #Nemolizumab #Tapinarof #Roflumilast #Biologics #ClinicalGuidelines #EvidenceBasedMedicine #AADUpdate2025 #AdultAD #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Focused Update: Guidelines of Care for the Management of Atopic Dermatitis in Adults. Davis, Dawn M.R. et al. Journal of the American Academy of Dermatology, Volume 93, Issue 3, 745.e1 - 745.e7 https://www.jaad.org/article/S0190-9622(25)02125-5/fulltext 

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

In this episode of Skinfluenced: The Skin Podcast, we have a brand new article to report on. Just a few days ago, a review of the safety of Platelet-Derived Growth Factor (PDGF) was released. Tune in to learn all about this topic of immense interest recently, as well as it’s importance in aesthetic and regenerative medicine.

This white paper highlights over 25 years of extensive safety research, discussing the rhPDGF-bb safety profile and track record of use. We'll specifically discuss the findings related to cancer, including the FDA black box warning! Tune in to understand the compelling evidence regarding the true safety of this powerful regenerative protein.

#PDGF #RegenerativeMedicine #GrowthFactorTherapy #AntiAging #SkinRejuvenation #CollagenBoost #Microneedling #HairRegeneration #CosmeticInnovation #Ariessence #HealingFaster #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

Link to Source(s):

Hee CK, Slade HB, Lynch SE. A Review of the Safety of Exogenously Applied Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications. Lynch Regenerative Medicine, LLC; 2025. RPT-001. https://www.lynchregen.com/wp-content/uploads/2025/09/RPT-001v1.0-A-Review-of-the-Safety-of-Exogenously-Applied-rhPDGF-vFinal.pdf